The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...